Introduction: Parkinson’s disease (PD) is the second common neurodegenerative disease following Alzheimer’s disease. Multifactorial risk factors including environmental, nutritional and genetic factors may affect the frequency, risks, and genetic features of PD in different geographic and ethnic regions. Background: Our aim was to investigate the sociodemographic and disease characteristics, cognitive performances of patients with PD in Nusaybin, a southeastern city, and Hendek a northwestern city which have different geographical-cultural status, and to investigate the possible effects of regional differences on disease characteristics. Method: This retrospective study includes the data of patients with the diagnosis of PD who presented to outpatient Neurology clinics of Hendek State Hospital which is a city in the northwestern region of Turkey between April 2017 and June 2018 and patients who presented to the outpatient Neurology clinics of Nusaybin State Hospital, which is a city in the southeastern region of Turkey between October 2015 and January 2017. SPSS.23c (Statistical package for Windows) database was used for statistical analysis. Results: Our study included 114 cases with Parkinson’s disease in Hendek and 96 cases in Nusaybin.The majority of patients had idiopathic PD (IPD) in both provinces (96.9% in Hendek, and 92.1% in Nusaybin). Educational status of female patients was significantly lower in Nusaybin when compared with Hendek (9.3% and 63.3%, respectively). Family history for IPD was significantly higher in Hendek than Nusaybin (31.7% and 9.9%, respectively). There was a positive correlation between educational status and cognitive performances of the patients in both groups. Negative correlation was found between standardized mini mental test (s-mmt) scores and stage, severity of IPD in both groups. Conclusion: The socio-cultural status of our country decreases by going from west to east. Thus knowledge about PD, accessibility to the hospitals and health centers with the opportunity to get optimum treatments may show variabilities in between the regions. We believe that our study provides a comparison of patients with PD in two different regions of our country with different geographic, genetic characteristics, and development levels.
References
[1]
Hughes, A.J., Daniel, S.E., Kilford, L. and Lees, A.J. (1992) Accuracy of Clinical Diagnosis of Idiopathic Parkinson’s Disease. A Clinico-Pathological Study, of 100 Cases. Journal of Neurology, Neurosurgery, and Psychiatry, 55, 181-184. https://doi.org/10.1136/jnnp.55.3.181
[2]
Chaudhuri, K.R., Healy, D.G. and Schapira, A.H. (2006) Non-Motor Symptoms of Parkinson’s Disease: Diagnosis and Management. The Lancet Neurology, 5, 235-245. https://doi.org/10.1016/S1474-4422(06)70373-8
[3]
Lim, S.Y. and Lang, A.E. (2010) The Nonmotor Symptoms of Parkinson’s Disease: An Overview. Movement Disorders, 25, S123-S130. https://doi.org/10.1002/mds.22786
[4]
Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., et al. (2007) Projected Number of People with Parkinson Disease in the Most Populous Nations, 2005 through 2030. Neurology, 68, 384-386. https://doi.org/10.1212/01.wnl.0000247740.47667.03
[5]
Kieburtz, K. and Wunderle, K.B. (2013) Parkinson’s Disease: Evidence for Environmental Risk Factors. Movement Disorders, 28, 8-13. https://doi.org/10.1002/mds.25150
[6]
Racette, B.A. and Willis, A.W. (2015) Time to Change the Blind Men and the Elephant Approach to Parkinson disease. Neurology, 85, 190-196. https://doi.org/10.1212/WNL.0000000000001739
[7]
Covy, J.P. and Giasson, B.I. α-Synuclein, Leucine-Rich Repeat Kinase-2, and Manganese in the Pathogenesis of Parkinson Disease. Neuro Toxicology, 32, 622-629. https://doi.org/10.1016/j.neuro.2011.01.003
[8]
Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., et al. (2011) MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Movement Disorders, 30, 1591-1601. https://doi.org/10.1002/mds.26424
[9]
Goetz, C.G., Fahn, S., Martinez-Martin, P., Poewe, W., Sampaio, C., et al. (2007) Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, Format, and Clinimetric Testing Plan. Movement Disorders, 22, 41-47. https://doi.org/10.1002/mds.21198
[10]
Hoehn, M.M. and Yahr, M.D. (1967) Parkinsonizm: Onset, Progression and Mortality. Neurology, 17, 427-442. https://doi.org/10.1212/WNL.17.5.427
[11]
Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975) “Mini-Mental State”: A Practical Method for Grading the Cognitive State of Patients for the Clinician. Journal of Psychiatric Research, 12, 189-198. https://doi.org/10.1016/0022-3956(75)90026-6
[12]
Güngen, C., Ertan, T., Eker, E., Yaşar, R. and Engin, F. (2002) Reliability and Validity of the Standardized Mini Mental State Examination in the Diagnosis of Mild Dementia in Turkish Population. Turkish Journal of Psychiatry, 13, 273-281.
[13]
de Rijk, M.C., Tzourio, C., Breteler, M.M., Dartigues, J.F., Amaducci, L., et al. (1997) Prevalence of Parkinsonism and Parkinson’s Disease in Europe: The EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s Disease. Journal of Neurology, Neurosurgery, and Psychiatry, 62, 10-15. https://doi.org/10.1136/jnnp.62.1.10
[14]
Twelves, D., Perkins, K.S.M. and Counsell, C. (2003) Systematic Review of Incidence Studies of Parkinson’s Disease. Movement Disorders, 18, 19-31. https://doi.org/10.1002/mds.10305
[15]
de Lau, L.M.L. and Breteler, M.M.B. (2006) Epidemiology of Parkinson’s Disease. The Lancet Neurology, 5, 525-535. https://doi.org/10.1016/S1474-4422(06)70471-9
[16]
Gillies, G.E., Pienaar, I.S., Vohra, S. and Qamhawi, Z. (2014) Sex Differences in Parkinson’s Disease. Frontiers in Neuroendocrinology, 35, 370-384. https://doi.org/10.1016/j.yfrne.2014.02.002
[17]
Keener, A.M. and Bordelon, Y.M. (2016) Parkinsonism. Seminars in Neurology, 36, 330-334. https://doi.org/10.1055/s-0036-1585097
[18]
Özbek, S.Z.M., Karlı, N., Özçakır, A., Yıldız, D. and Aslan, D. (2009) A Population-Based Survey to Determine the Prevalence of Movement Disorders in Orhangazi District of Bursa, Turkey. Turkish Journal of Neurology, 15, 109-118.
[19]
Bolayır, E.T.A., Topalkara, K., Akyüz, A. and Topaktas, S. (2002) Sivas İl Merkezinde Parkinson Hastalığı Prevalansı. Çukurova üniversitesi Tıp Fakültesi Dergisi, 24, 65-68.
[20]
Torun, S., Uysal, M., Gücüyener, D. and Özdemir, G. (1995) Parkinson’s Disease in Eskişehir, Turkey. European Journal of Neurology, 2, 44-45.
[21]
Durmus, H., Gokalp, M.A. and Hanagasi, H.A. (2015) Prevalence of Parkinson’s Disease in Baskale, Turkey: A Population Based Study. Neurological Sciences, 36, 411-413. https://doi.org/10.1007/s10072-014-1988-x
[22]
Seidl, S.E., Santiago, J.A., Bilyk, H. and Potashkin, J.A. (2014) The Emerging Role of Nutrition in Parkinson’s Disease. Frontiers in Aging Neuroscience, 6, 36. https://doi.org/10.3389/fnagi.2014.00036
[23]
Lesage, S. and Brice, A. (2009) Parkinson’s Disease: From Monogenic Forms to Genetic Susceptibility Factors. Human Molecular Genetics, 18, R48-R59. https://doi.org/10.1093/hmg/ddp012
[24]
Lohmann, E., Dursun, B., Lesagec, S., Hanagasi, H.A., Sevinc, G., et al. (2012) Genetic Bases and Phenotypes of Autosomal Recessive Parkinson Disease in a Turkish Population. European Journal of Neurology, 19, 769-77. https://doi.org/10.1111/j.1468-1331.2011.03639.x
[25]
Riedel, O., Klotsche, J., Spottke, A., Deuschl, G., Förstl, H., et al. (2008) Cognitive Impairment in 873 Patients with Idiopathic Parkinson’s Disease. Results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). Journal of Neurology, 255, 255-264. https://doi.org/10.1007/s00415-008-0720-2
[26]
Riedel, O., Klotsche, J., Spottke, A., Deuschl, G., Förstl, H., et al. (2010) Frequency of Dementia, Depression, and Other Neuropsychiatric Symptoms in 1,449 Outpatients with Parkinson’s Disease. Journal of Neurology, 257, 1073-1082. https://doi.org/10.1007/s00415-010-5465-z
[27]
Pigott, K., Rick, J., Xie, S.X., Hurtig, H., Chen-Plotkin, A., et al. (2015) Longitudinal Study of Normal Cognition in Parkinson Disease. Neurology, 85, 1276-1282. https://doi.org/10.1212/WNL.0000000000002001
[28]
Pai, M.C. and Chan, S.H. (2001) Education and Cognitive Decline in Parkinson’s Disease: A Study of 102 Patients. Acta Neurologica Scandinavica, 103, 243-247.
[29]
Mamikonyan, E., Moberg, P.J., Siderowf, A., Duda, J.E., Have, T.T., et al. (2009) Mild Cognitive Impairment Is Common in Parkinson’s Disease Patients with Normal Mini-Mental State Examination (MMSE) Scores. Parkinsonism & Related Disorders, 15, 226-231. https://doi.org/10.1016/j.parkreldis.2008.05.006
[30]
Hawkes, C.H., del Tredici, K. and Braak, H. (2010) A Timeline for Parkinson’s Disease. Parkinsonism & Related Disorders, 16, 79-84. https://doi.org/10.1016/j.parkreldis.2009.08.007
[31]
Meireles, J. and Massano, J. (2012) Cognitive Impairment and Dementia in Parkinson’s Disease: Clinical Features, Diagnosis, and Management. Frontiers in Neurology, 3, 88. https://doi.org/10.3389/fneur.2012.00088
[32]
Xu, Y., Yang, J. and Shang, H. (2016) Meta-Analysis of Risk Factors for Parkinson’s Disease Dementia. Translational Neurodegeneration, 5, Article No. 11. https://doi.org/10.1186/s40035-016-0058-0
